| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $334,058 | 11 | 100 |
Sells | $0 | 0 | 0 |
| Schall Thomas J. | director | 2 | $124,066 | 0 | $0 | $124,066 |
| Zeskind Benjamin J. | PRESIDENT AND CEO | 3 | $85,023 | 0 | $0 | $85,023 |
| Feinberg Peter | director | 1 | $63,188 | 0 | $0 | $63,188 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 2 | $34,616 | 0 | $0 | $34,616 |
| HAUSMAN DIANA | director | 1 | $19,863 | 0 | $0 | $19,863 |
| Brakewood Harold Eugene | Chief Business Officer | 1 | $4,804 | 0 | $0 | $4,804 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER | 1 | $2,499 | 0 | $0 | $2,499 |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Over the last 12 months, insiders at Immuneering Corporation have bought $334,058 and sold $0 worth of Immuneering Corporation stock.
On average, over the past 5 years, insiders at Immuneering Corporation have bought $6.36M and sold $3.91M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schall Thomas J. (director) — $124,066. Zeskind Benjamin J. (PRESIDENT AND CEO) — $85,023. Feinberg Peter (director) — $63,188.
The last purchase of 7,015 shares for transaction amount of $24,792 was made by Zeskind Benjamin J. (PRESIDENT AND CEO) on 2025‑07‑02.
| 2025-07-02 | Zeskind Benjamin J. | PRESIDENT AND CEO | 7,015 0.0192% | $3.53 | $24,792 | +13.89% | ||
| 2025-07-02 | Neufeld Leah R | CHIEF PEOPLE OFFICER | 700 0.0019% | $3.57 | $2,499 | +13.89% | ||
| 2025-07-02 | HAUSMAN DIANA | director | 5,500 0.0154% | $3.61 | $19,863 | +13.89% | ||
| 2025-07-01 | Zeskind Benjamin J. | PRESIDENT AND CEO | 2,985 0.0081% | $3.38 | $10,087 | +18.46% | ||
| 2025-06-27 | Schall Thomas J. | director | 9,500 0.0274% | $3.66 | $34,788 | +14.02% | ||
| 2025-06-23 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 6,007 0.0166% | $2.43 | $14,596 | +60.35% | ||
| 2025-06-20 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 7,415 0.0217% | $2.70 | $20,020 | +52.73% | ||
| 2025-06-20 | Brakewood Harold Eugene | Chief Business Officer | 1,900 0.0052% | $2.53 | $4,804 | +52.73% | ||
| 2025-06-18 | Zeskind Benjamin J. | PRESIDENT AND CEO | 21,000 0.0503% | $2.39 | $50,144 | +35.56% | ||
| 2025-06-18 | Feinberg Peter | director | 25,000 0.0634% | $2.53 | $63,188 | +35.56% | ||
| 2025-06-17 | Schall Thomas J. | director | 40,485 0.1363% | $2.21 | $89,278 | +97.80% | ||
| 2024-04-01 | Sale | Cormorant Asset Management, LP | 10 percent owner | 400,000 1.4407% | $2.90 | $1.16M | -38.55% | |
| 2024-03-22 | Feinberg Peter | director | 25,000 0.0853% | $2.55 | $63,713 | -32.16% | ||
| 2024-03-22 | Morales Mallory | Chief Accounting Officer | 393 0.0013% | $2.55 | $1,000 | -32.16% | ||
| 2024-03-22 | Brakewood Harold Eugene | Chief Business Officer | 3,900 0.0134% | $2.57 | $10,015 | -32.16% | ||
| 2024-03-22 | Schall Thomas J. | director | 2,900 0.0099% | $2.55 | $7,385 | -32.16% | ||
| 2024-03-21 | Morales Mallory | Chief Accounting Officer | 1,107 0.0038% | $2.72 | $3,009 | -36.08% | ||
| 2024-03-20 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 7,000 0.0246% | $2.86 | $20,020 | -37.23% | ||
| 2024-03-20 | Neufeld Leah R | CHIEF PEOPLE OFFICER | 3,818 0.0135% | $2.88 | $10,993 | -37.23% | ||
| 2024-03-19 | Zeskind Benjamin J. | PRESIDENT AND CEO | 20,000 0.0735% | $2.77 | $55,326 | -31.32% |
| Zeskind Benjamin J. | PRESIDENT AND CEO | 2312852 6.4271% | $9.55M | 7 | 0 | <0.0001% |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 359318 0.9985% | $1.48M | 6 | 0 | <0.0001% |
| Feinberg Peter | director | 136766 0.3801% | $564,843.58 | 8 | 0 | <0.0001% |
| Schall Thomas J. | director | 52885 0.147% | $218,415.05 | 3 | 0 | <0.0001% |
| Neufeld Leah R | CHIEF PEOPLE OFFICER | 10729 0.0298% | $44,310.77 | 2 | 0 | <0.0001% |
| Brakewood Harold Eugene | Chief Business Officer | 5800 0.0161% | $23,954.00 | 2 | 0 | <0.0001% |
| HAUSMAN DIANA | director | 3000 0.0083% | $12,390.00 | 1 | 0 | |
| Cormorant Asset Management, LP | 10 percent owner | 2895273 8.0456% | $11.96M | 1 | 3 | <0.0001% |
| CARPENTER ROBERT J | director | 1148839 3.1925% | $4.74M | 1 | 0 | <0.0001% |
| BERMAN ANN E | director | 67465 0.1875% | $278,630.45 | 3 | 0 | <0.0001% |
| KEATING LAURIE | 14000 0.0389% | $57,820.00 | 2 | 0 | <0.0001% | |
| Morales Mallory | Chief Accounting Officer | 8278 0.023% | $34,188.14 | 2 | 0 | <0.0001% |
| Amin Biren | CFO, TREASURER | 7898 0.0219% | $32,618.74 | 2 | 0 | <0.0001% |
| Barrett Scott | CHIEF MEDICAL OFFICER | 7563 0.021% | $31,235.19 | 2 | 0 | <0.0001% |
| Bookman Michael | GENERAL COUNSEL AND SECRETARY | 2402 0.0067% | $9,920.26 | 2 | 0 | <0.0001% |
$7,237,838 | 92 | -8.14% | $162.97M | |
$5,558,275 | 76 | -5.88% | $154.94M | |
$140,938,207 | 36 | 14.75% | $168.61M | |
Immuneering Corporation (IMRX) | $18,752,549 | 33 | -28.39% | $148.62M |
$1,351,643 | 19 | 46.45% | $142.67M | |
$111,692,551 | 18 | 13.51% | $142.68M | |
$448,999,793 | 15 | -19.99% | $135.53M | |
$10,143,329 | 12 | 11.84% | $161.18M | |
$73,968,137 | 12 | -34.52% | $135.06M | |
$456,220 | 9 | 34.12% | $167.04M | |
$13,043,783 | 8 | 732.82% | $150.2M | |
$22,090,972 | 7 | -3.49% | $132.51M | |
$556,839 | 5 | 13.42% | $164.74M | |
$63,981 | 5 | -11.55% | $136.79M | |
$32,289,200 | 3 | -5.46% | $158.99M | |
$9,999,990 | 2 | 25.53% | $137.77M | |
$20,020,000 | 1 | -75.24% | $168.55M | |
$300,016 | 1 | -50.33% | $136.83M | |
$5,512,500 | 1 | -7.91% | $139.97M |
| Increased Positions | 14 | +25.93% | 916,571 | +21.54% |
| Decreased Positions | 21 | -38.89% | 673,123 | -15.82% |
| New Positions | 5 | New | 43,705 | New |
| Sold Out Positions | 12 | Sold Out | 360,589 | Sold Out |
| Total Postitions | 47 | -12.96% | 4M | +5.72% |
| Vanguard Group Inc | $1,311.00 | 2.94% | 1.06M | -13,400 | -1.25% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $951.00 | 2.13% | 767,124 | -43,003 | -5.31% | 2024-12-31 |
| Morgan Stanley | $563.00 | 1.26% | 454,100 | +4,789 | +1.07% | 2024-12-31 |
| Blackrock, Inc. | $392.00 | 0.88% | 316,530 | -2,233 | -0.7% | 2025-03-31 |
| Southport Management, L.L.C. | $267.00 | 0.6% | 215,000 | +10,000 | +4.88% | 2024-12-31 |
| Geode Capital Management, Llc | $258.00 | 0.58% | 208,387 | -1,254 | -0.6% | 2024-12-31 |
| Rockefeller Capital Management L.P. | $220.00 | 0.49% | 177,377 | +177,377 | New | 2024-12-31 |
| Td Asset Management Inc | $187.00 | 0.42% | 150,876 | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $128.00 | 0.29% | 102,936 | -143,334 | -58.2% | 2024-12-31 |
| Manufacturers Life Insurance Company, The | $102.00 | 0.23% | 82,638 | 0 | 0% | 2024-12-31 |